HK Stock Market Move | METIS TECHBIO-P(07666) rose over 11% intraday, partnering with Joinn Laboratories to build an mRNA drug innovative R&D and industrialization manufacturing platform.

METIS TECHBIO-P(07666) rose over 11% intraday, up 10.67% as of press time, at HK$15.12, with a turnover of HK$83.3917 million. On the news front, recently, according to METIS TechBio's official WeChat account, the company has formally signed a joint venture agreement with Joinn Biologics to jointly establish a JV company, Zhaotai Zhiyao, to build an mRNA drug innovative R&D and industrialization manufacturing platform. At present, the first project under the partnership between the two parties has been launched. According to the agreement, METIS TechBio will provide design and delivery capabilities on the upstream side, and NanoForge has achieved targeted delivery to 8 key organs and tissues in the human body. Ms. Feng Yuxia, Chairman of Joinn Laboratories, said: "The joint establishment of a JV company by Joinn Biologics and METIS TechBio is an important practice of the two parties complementing each other's strengths and pursuing coordinated development. METIS TechBio has outstanding innovation capabilities in AI-driven mRNA sequence design and nano-delivery, while Joinn Biologics has accumulated solid process development and industrialization experience in the large-molecule drug CDMO field. It is hoped that through this cooperation, the R&D and manufacturing capabilities of both parties will be effectively integrated to jointly provide one-stop services from design to production for mRNA new drug R&D."